H.C. Wainwright Starts Serina THerapeutics (SER) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts SER Hot Sheet
Price: $1.94 -3%
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Join SI Premium – FREE
H.C. Wainwright analyst Raghuram Selvaraju initiates coverage on Serina THerapeutics (NYSE: SER) with a Buy rating and a price target of $15.00.
For an analyst ratings summary and ratings history on Serina THerapeutics click here. For more ratings news on Serina THerapeutics click here.
Shares of Serina THerapeutics closed at $5.91 yesterday.
You May Also Be Interested In
- Canaccord Starts Innovaero Technologies (INN:AU) at Buy
- Barclays Starts Quintiles (Q) at Overweight
- Deutsche Bank Starts Columbia Banking System (COLB) at Hold
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
